Valiant Organics Limited has informed the Exchange about Investor Presentation
VALIANTORG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Valiant Organics reported a significant turnaround in FY26 with consolidated revenue of INR 7,388 Mn (up 3% YoY) and EBITDA of INR 882 Mn (up 64% YoY). EBITDA margin expanded sharply by 447 basis points to 11.94% compared to 7.47% in FY25, driven by structural cost optimization including raw material optimization and tighter overhead control. The company posted PAT of INR 332 Mn versus a loss of INR 34 Mn in FY25. Q4-FY26 alone showed revenue of INR 2,178 Mn (up 7% YoY) with EBITDA margin at 12.17%. Finance costs declined 23% YoY to INR 182 Mn. The company manufactures specialty chemicals including chlorophenol derivatives and PNA, serving pharmaceuticals, agrochemicals, dyes and pigments industries across 6 manufacturing units with 70,000 TPA capacity.
Strong margin expansion and return to profitability after two years of losses signals operational recovery and better cost management, which could be positive for the stock. The 23% reduction in finance costs also indicates improving financial health.